Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma 3Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × polatuzumab vedotin × Clear all
NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1/2 Completed
117 enrolled 26 charts
Lymphoid

Lymphoma, B-Cell

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Academic and Community Cancer Research United

Phase 2 Terminated
3 enrolled 11 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡